Greater Paris University Hospitals (AP-HP) has deployed the Implicity platform for the remote monitoring of its patients with implantable cardiac devices

The European leader in remote monitoring of implantable cardiac devices, Implicity, was selected during a call for tenders within the AP-HP to be used for eight hospitals: Hôpital Européen Georges-Pompidou, Pitié Salpêtrière, Henri-Mondor, Bichat-Claude Bernard, Bicêtre-Béclère-Paul Brousse and Necker-Enfants Malades.

Recognized as a medical act and reimbursed since November 2017 as part of the ETAPES(1) program, remote monitoring allows clinicians to remain up to date on their patients equipped with implantable defibrillators and pacemakers. Recommended by international scientific societies, telemonitoring meets a major public health need by improving healthcare quality and reducing mortality by 38% (2) within 1 year. AP-HP was a pioneer of remote care by offering this innovative technology to patients, even before the ETAPES program was implemented.

To meet the technical requirements of the reimbursement system and to optimize the remote monitoring of patients, the AP-HP has set up a dedicated platform to support the patient volume increase in the implantation centers of the group and the research activity.

Accessible 24/7, the SaaS platform Implicity is a medical decision support tool that aggregates data from cardiac implantable electronic devices from five manufacturers (Abbott, Biotronik, Boston Scientific, Medtronic and Microport). Through a single connection interface, medical staff can monitor and interpret cardiac events of patients equipped with all cardiac implantable devices on the market. The homogenization of monitoring facilitates remote monitoring: better identification of alerts, optimization of interactions between physicians and paramedics in charge of the follow-up, production of automated medical reports, assistance with invoicing within the framework of ETAPES program …

Increased demand for remote cardiac monitoring during the pandemic

Today, the technical integration of the platform is effective and the teams of all eight AP-HP implanting centers are trained and operational. In the context of the pandemic, remote monitoring of patients has become essential to ensure the continuity of care for at-risk patients, while respecting social distancing measures and reducing infection risks.

As of July 2021, nearly 5,000 patients with implantable cardiac devices were remotely  monitored daily within the AP-HP.

“Our goal at Hôpital Européen Georges-Pompidou (HEGP) was to integrate a technology allowing better patient care while optimizing medical and nurse time efficiency. AP-HP has chosen innovation to relieve medical teams of time-consuming administrative daily tasks, thanks to automation and artificial intelligence. This unique platform clearly saves time for medical teams. Above all, it allows us to collect data for research and to support a program that is unique in Europe, the DAIPP consortium. », declares Prof. Eloi Marijon, cardiology department, Hôpital Européen Georges-Pompidou, Paris.

Implicity platform – A technical solution for research

With a robust quality management system, certified ISO27001, “health data host” and compliant with the European GDPR regulation, Implicity platform was chosen for the research program DAI-PP (cohort of 10,000 Patients with an Implantable Automatic Defibrillator, who will be monitored in real time for 10 years), carried out in collaboration with INSERM and Clinique Pasteur, and supported by the French Society of Cardiology. At the initiative of a consortium of 19 French University Hospital Centers and private centers, including AP-HP, the Pasteur clinic in Toulouse and the Poitiers University Hospital, this project is a large-scale European initiative in its field.

A collaboration that confirms the value provided to medical teams and patients

“For Implicity, this collaboration is very meaningful and has confirmed the value brought to medical teams for optimizing patient follow-up while allowing valuable feedback from the industry. At Implicity, our goal is to improve patient care through artificial intelligence and unlock the potential of medical data for research. This collaboration with AP-HP on both aspects “routine care” and “research” allows us to achieve our core mission”, comments Dr. Arnaud Rosier, cardiologist and founder of Implicity.


(1) ETAPES (Expérimentations de Télémédecine pour l’Amélioration des Parcours En Santé). Ces expérimentations portent sur cinq pathologies: l’insuffisance cardiaque, l’insuffisance rénale, l’insuffisance respiratoire, le diabète et la télésurveillance des prothèses cardiaques implantables. L’article 54 de la loi de financement de la sécurité sociale (LFSS) pour 2018 a reconduit le programme Etapes pour une durée de quatre ans (2018-2021).
(2) Hindricks, et al. “Daily remote monitoring of implantable cardioverter-defibrillators: insights from the pooled patient-level datafrom three randomized controlled trials (IN-TIME, ECOST, TRUST)”, 2017

About Assistance Publique – Hôpitaux de Paris / Greater Paris University Hospitals

The leading hospital and university centre (CHU) in Europe, Greater Paris University Hospitals and its 39 hospitals are organised into six hospital-university groups (AP-HP. Centre – Université de Paris ; AP-HP. Sorbonne Université ; AP-HP. Nord – Université de Paris ; AP-HP. Université Paris Saclay ; AP-HP. Hôpitaux Universitaires Henri Mondor et AP-HP. Hôpitaux Universitaires Paris Seine-Saint-Denis) and are centred around five universities in the Île-de-France region. Closely linked to large research bodies, Greater Paris University Hospitals include three international hospital-university institutes (Institut du Cerveau, ICAN, IMAGINE) and the largest French health data repository (EDS). As a major stakeholder in applied research and health innovation, Greater Paris University Hospitals hold a portfolio of 650 active patents, and each year its clinicians sign off nearly 9,000 scientific publications and over 4,000 research projects are under development, all promoters combined. In 2020, Greater Paris University Hospitals were awarded the Institut Carnot label, which is recognition of the quality of partner research: Carnot@AP-HP offers industrial stakeholders applied and clinical research solutions in the health sector. In 2015, Greater Paris University Hospitals also founded the Greater Paris University Hospitals Research Foundation to support the biomedical and health research performed in all its hospitals.

About Implicity

Implicity provides a remote monitoring and research platform used by Independent Diagnostic Testing Facilities and cardiac electrophysiology centers to deliver high-quality care for  patients with connected Cardiac Implantable Electronic Devices. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers. Furthermore, Implicity carries out R&D on AI-based algorithms aiming at improving patient care and serving the future of preventive medicine. Implicity has been the first private company authorized to access the Health Data Hub*, one of largest databases of patients with heart diseases in the world, supporting the development of its AI solutions.  Implicity covers more than 30,000 patients in over 60 medical facilities across Europe and the United States. For more information visit:

Read the French version of the press release

Posted on

1 September 2021